Insulin-like growth factor receptor (IGF-1R) in breast cancer subtypes

2011 ◽  
Vol 132 (1) ◽  
pp. 131-142 ◽  
Author(s):  
Rinat Yerushalmi ◽  
Karen A. Gelmon ◽  
Samuel Leung ◽  
Dongxia Gao ◽  
Maggie Cheang ◽  
...  
PLoS ONE ◽  
2014 ◽  
Vol 9 (3) ◽  
pp. e91407 ◽  
Author(s):  
Giannis Mountzios ◽  
Dimitra Aivazi ◽  
Ioannis Kostopoulos ◽  
Helen P. Kourea ◽  
George Kouvatseas ◽  
...  

2020 ◽  
Vol 34 (S1) ◽  
pp. 1-1
Author(s):  
Iman M. Talaat ◽  
Wafaa S. Ramadan ◽  
Mahmood Y. Hachim ◽  
Ibrahim Y. Hachim ◽  
Nada S. Yakout ◽  
...  

2009 ◽  
Author(s):  
R Yerushalmi ◽  
B Gilks ◽  
T Nielsen ◽  
S Leang ◽  
M Cheang ◽  
...  

2021 ◽  
pp. 107815522199163
Author(s):  
Homa Seyedmirzaei ◽  
Mahsa Keshavarz-Fathi ◽  
Sepideh Razi ◽  
Masoumeh Gity ◽  
Nima Rezaei

Objective Breast cancer is responsible for most of the cancer-induced deaths in women around the world. The current review will discuss different approaches of targeting HER2, an epidermal growth factor overexpressed in 30% of breast cancer cases. Data sources We conducted a search on Pubmed and Scopus databases to find studies relevant to HER2+ breast cancers and targeting HER2 as means of immunotherapy. Out of 1043 articles, 105 studies were included in this review. Data summary As well as the introduction of HER2 and breast cancer subtypes, we discussed various aspects of HER2-targeting immunotherapy including monoclonal antibodies, Antibody-drug conjugates (ADCs), Chimeric Antigen Receptor (CAR) T-cells and vaccines. Conclusions Despite several ways of controlling breast cancer, the need to investigate new drugs and approaches seems to be much significant as this cancer still has a heavy burden on people’s health and survival.


2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e11511-e11511 ◽  
Author(s):  
Isa Dede ◽  
Gungor Utkan ◽  
Hakan Akbulut ◽  
Yuksel Urun ◽  
Dilsa Mizrak ◽  
...  

e11511 Background: Carcinoembryonic antigen (CEA) and carbohydrate antigen (CA) 15-3 are frequently elevated in patients with metastatic breast cancer (MBC). In this study we aimed to correlate levels according to breast cancersubtypes with MBC. Methods: From January 2008 to December 2012, ninety-eight patients with MBC who were treated at Ankara University School Of Medicine, Department of Medical Onkology were included in this study.Serum levels of CEA and CA 15-3were measured and compared according to tumor estrogen receptor (ER), progesteron receptor (PR), and human epidermal growth factor receptor 2 (HER2) status. Results: In this cohort, overall ER,PR and HER2 positivity rates were 65 %,68%,and 58%, retrospectively. Positivite ER status was associated with elevated levels of CA 15-3 and cea. Of these, CA 15-3 levels elevated in 40.5% of ER positivite and 24.1 % of ER negativite patients (p=0.027). Similarly, 46.8 % of ER positivite and 18.2% of ER negativite patients had elevated levels of CEA (P=0.022). no association between PR and HER2 status and tumor markers was observed. Conclusions: The breast cancer subtypes are correlated with serum levels of tumor markers in patients with MBC. Tumor markers elevation may be associated with biological background of breast cancer subtypes. Further validation is needed to determine the role of these markers in diffrent tumor types for monitoring patients with MBC.


Sign in / Sign up

Export Citation Format

Share Document